Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

531
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
531
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

640
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
640
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

206
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
206
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

544
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
544
Hypersensitivities01:30

Hypersensitivities

1.1K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
1.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

403
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
403

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.

The Journal of dermatology·2026
Same author

Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.

Frontiers in immunology·2026
Same author

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

Dermatology and therapy·2026
Same author

Topological model selection: a case-study in tumour-induced angiogenesis.

Bioinformatics (Oxford, England)·2026
Same author

Correction to: Atopic Comorbidities and Topical Steroids in Early Childhood Atopic Dermatitis: Are We Missing a Piece of the Puzzle?

Clinical reviews in allergy & immunology·2026
Same author

Atopic Comorbidities and Topical Steroids in Early Childhood Atopic Dermatitis: Are We Missing a Piece of the Puzzle?

Clinical reviews in allergy & immunology·2026
Same journal

Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.

Dermatology and therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.

Dermatology and therapy·2026
Same journal

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.

Dermatology and therapy·2026
Same journal

Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.

Dermatology and therapy·2026
Same journal

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.

Dermatology and therapy·2026
Same journal

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials.

Dermatology and therapy·2026
See all related articles

Related Experiment Video

Updated: Sep 22, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.9K

Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.

El-Bdaoui Haddad1, Sonya L Cyr2, Kazuhiko Arima3

  • 1Sanofi, 450 Water Street, Cambridge, MA, USA. El-Bdaoui.Haddad@sanofi.com.

Dermatology and Therapy
|May 21, 2022
PubMed
Summary
This summary is machine-generated.

Type 2 immunity protects against parasites but drives allergic diseases like atopic dermatitis. Therapies targeting type 2 inflammation pathways are emerging to treat these conditions.

Keywords:
Atopic dermatitisBiologicCytokineJanus kinaseType 2 inflammation

More Related Videos

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System
10:25

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

7.1K
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.5K

Related Experiment Videos

Last Updated: Sep 22, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.9K
Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System
10:25

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

7.1K
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.5K

Area of Science:

  • Immunology
  • Dermatology
  • Allergology

Background:

  • Type 2 immunity evolved to combat helminth infections, involving innate and adaptive immune cells for parasite expulsion and tissue repair.
  • Aberrant type 2 immune responses are implicated in allergic conditions such as atopic dermatitis (AD) and asthma, characterized by chronic inflammation.
  • Key type 2 cytokines include IL-4, IL-5, IL-13, IL-31, IL-25, IL-33, and thymic stromal lymphopoietin, produced by immune and tissue cells.

Purpose of the Study:

  • To review the role of type 2 inflammation in inflammatory diseases.
  • To discuss current and future therapies targeting type 2 pathways, with a specific focus on atopic dermatitis.

Main Methods:

  • Review of scientific literature on type 2 immunity and inflammatory diseases.
  • Analysis of the mechanisms of action for various therapeutic strategies targeting type 2 pathways.

Main Results:

  • IL-4 and IL-13 are central to type 2 inflammation, promoting Th2 cell differentiation, decreased barrier function, IgE production, fibrosis, and pruritus.
  • IL-5 regulates eosinophils, crucial for type 2 immunity.
  • In AD, IL-4, IL-13, and IL-31 contribute to itch and inflammation, creating a cycle of exacerbation.

Conclusions:

  • Type 2 inflammation plays a dual role in host defense and disease pathogenesis.
  • Targeting type 2 cytokines, their receptors, or intracellular signaling pathways (e.g., JAK inhibitors) represents a promising therapeutic approach for type 2-driven inflammatory diseases like AD.